16 sgRNAs (named V1-V16), 15 induced significant increases in VEGFA protein expression when coexpressed with dCas9-VP64 in HEK293 cells (Fig. 1c) . Expression of a codon-optimized sequence encoding dCas9-VP64 did not enhance observed VEGFA activation (Supplementary Fig. 1 ). Expression of each of the 16 sgRNAs alone, of dCas9-VP64 alone or of dCas9-VP64 together with an 'off-target' sgRNA designed to bind an EGFP reporter gene sequence all did not induce elevated VEGFA expression (Fig. 1c) . There was no substantial correlation between the activities of wild-type Cas9 nuclease and of dCas9-VP64 for the 16 different sgRNAs (Supplementary Fig. 2 ). In addition, in experiments with a subset of three sgRNAs, activation depended on the presence of the VP64 domain ( Supplementary  Fig. 3 ). The lack of activation with RNA-guided dCas9 alone is not due to lack of protein expression; in our experiments, dCas9 was typically expressed at higher levels than dCas9-VP64, as assessed by western blot (Supplementary Fig. 4 ). This latter observation suggests that activity of dCas9-VP64 might be improved if its stability were to be improved.
16 sgRNAs (named V1-V16), 15 induced significant increases in VEGFA protein expression when coexpressed with dCas9-VP64 in HEK293 cells (Fig. 1c) . Expression of a codon-optimized sequence encoding dCas9-VP64 did not enhance observed VEGFA activation (Supplementary Fig. 1 ). Expression of each of the 16 sgRNAs alone, of dCas9-VP64 alone or of dCas9-VP64 together with an 'off-target' sgRNA designed to bind an EGFP reporter gene sequence all did not induce elevated VEGFA expression (Fig. 1c) . There was no substantial correlation between the activities of wild-type Cas9 nuclease and of dCas9-VP64 for the 16 different sgRNAs (Supplementary Fig. 2 ). In addition, in experiments with a subset of three sgRNAs, activation depended on the presence of the VP64 domain ( Supplementary  Fig. 3 ). The lack of activation with RNA-guided dCas9 alone is not due to lack of protein expression; in our experiments, dCas9 was typically expressed at higher levels than dCas9-VP64, as assessed by western blot (Supplementary Fig. 4 ). This latter observation suggests that activity of dCas9-VP64 might be improved if its stability were to be improved.
We next tested whether RNA-guided activators could also induce expression of the human NTF3 gene. To do this, we used six sgRNAs targeted to sequences in a predicted DNase I hypersensitive site in the human NTF3 promoter and dCas9-VP64 expressed from a construct that was codon-optimized for expression in human cells ( Fig. 1d and Online Methods). All six sgRNAs induced significant increases in NTF3 transcript levels ( Fig. 1e) with mean levels of activated expression varying over a fourfold range. In experiments with a subset of three sgRNAs, we again observed that activation depended on the VP64 domain ( Supplementary Figs. 3 and 4) . Decreasing the amounts of sgRNA and dCas9-VP64 expression plasmids transfected resulted in less activation of the NTF3 gene (Fig. 1e) .
We envisioned that expression of multiple guide RNAs in a single cell might enable synergistic activation of endogenous gene targets as recently described for transcription activator-like effector (TALE)-based activators 12, 13 , thereby enabling combinatorial control of endogenous gene expression over a wider dynamic range. Coexpression of dCas9-VP64 with four sgRNAs (V1-V4) as well as with subsets of three of these four sgRNAs induced synergistic activation of VEGFA protein expression (Fig. 2a) . Similarly, coexpression of dCas9-VP64 with three sgRNAs (N4, N5 and N6) and all possible pairs of these sgRNAs led to large increases in NTF3 expression with three of the four combinations yielding a mean NTF3 mRNA expression greater than the expected additive effects of the individual activators (Fig. 2b) . Because synergy is mediated by binding of multiple activators to a single promoter, our results strongly suggest that multiple sgRNA-dCas9-VP64 complexes can function efficiently together in a single cell. CRISPR systems from bacteria 1 have enabled the development of RNA-guided nuclease technology for targeted genome editing [2] [3] [4] [5] [6] [7] . The Streptococcus pyogenes Cas9 can be directed by a ~100-nucleotide (nt) single-guide RNA (sgRNA) to a target genomic DNA sequence that is complementary to the first 20 nt of the sgRNA and is flanked by a protospacer-adjacent motif sequence of the form NGG, where N is any nucleotide 4, 5 . RNA-mediated recruitment of a catalytically inactive form of Cas9 (here referred to as dCas9) can induce repression of endogenous genes in bacterial and human cells 8, 9 . In addition, fusions of dCas9 to effector domains have been used to activate reporter genes in Escherichia coli and human cells 9, 10 and to repress endogenous genes in human cells 10 . Here we determined whether dCas9-based transcriptional activators could regulate endogenous gene expression in human cells using single and multiple sgRNAs.
To do this, we constructed a dCas9-VP64 fusion protein consisting of the synthetic VP64 activation domain 11 linked to the C terminus of dCas9 ( Fig. 1a and Online Methods) and tested the capacity of this fusion to activate expression of the human VEGFA gene. We targeted the dCas9-VP64 protein to specific sites in the genome of human embryonic kidney 293 (HEK293) cells using 16 prevalidated sgRNAs that we had observed could be expressed in HEK293 cells and could induce Cas9-mediated cleavage at their target sites (Supplementary Table 1 ). These sgRNAs bind sequences within three DNase I hypersensitive sites located upstream, downstream or at the VEGFA gene transcription start site (Fig. 1b) . Of these Our experiments define an RNA-guided activator platform to induce expression of endogenous genes in human cells. Of 22 sgRNAs tested, 21 induced significant gene activation at the VEGFA and NTF3 gene promoters. sgRNAs targeting sites on either DNA strand and at positions upstream, downstream or at the transcription start site all showed activity. The magnitude of VEGFA and NTF3 activation by dCas9-VP64 activators was generally lower than what we previously observed using VP64 TALEbased activators at these genes 12 . In addition, these activators also showed substantial variability in activity even when targeted to the same locus, as has also been observed with engineered zinc finger-based and TALE-based activators 12, 14 . Potential causes of this variation include position-dependent effects, differences in binding to DNA or competition for binding with endogenous transcription factors. We did not observe any correlation between the nucleotide composition of the sgRNA complementarity region and the extent of activation (Supplementary Fig. 5 ). Larger-scale 
O ff -t a rg e t N o n e sgRNA NTF3 brIef CommunICatIons npg testing will be needed to more definitively define the activity determinants of dCas9-VP64 activators. Another important future goal will be to define the extent of off-target effects induced by RNA-guided activators. sgRNA-guided Cas9 nuclease can induce off-target mutations at sites that differ by as many as five positions from the on-target sequence in human cells, but bona fide off-target sites can be difficult to predict 15 . However, although nucleases can in principle alter the DNA sequence of any off-target site, a transcriptional activator may not always induce changes in gene expression when it binds to an off-target site. Consistent with this, a recent study revealed minimal, if any, changes in gene expression changes in human cells (as measured by RNA-seq) induced by an RNA-guided dCas9-KRAB repression domain fusion 10 .
In summary, our results (and those of others 10 ) provide proof of principle that heterologous effector domains can be fused to dCas9 without disrupting its ability to complex and function with sgRNAs in mammalian cells. These findings open the door to fusion of dCas9 to other effector domains. The simplicity of sgRNA-mediated targeting together with the ability to recruit dCas9 fusions in multiplex fashion should enable many applications of these tools for biological research. Table 2 ). These fragments were ligated into BsmBI-digested plasmid pMLM3636 to yield DNA encoding a chimeric ~100 nt single-chain guide RNA 3, 5 under the control of a human U6 promoter. The pMLM3636 plasmid and its full DNA sequence are available from Addgene (http://www.addgene.org/crispr-cas).
Construction of dCas9-VP64 expression plasmids. DNA encoding the Cas9 nuclease harboring inactivating D10A and H840A substitutions (dCas9) was amplified by PCR from plasmid pMJ841 (Addgene plasmid 39318) using primers that add a T7 promoter site 5ʹ to the start codon and a nuclear localization signal at the 3ʹ end of the Cas9 coding sequences and cloned into a plasmid containing a CMV promoter as previously described 3 to yield plasmid pMLM3629. Oligonucleotides encoding a triple Flag epitope were annealed and cloned into XhoI and PstI sites in plasmid pMLM3629 to generate plasmid pMLM3647 expressing dCas9 with a C-terminal Flag tag. DNA sequence encoding a Gly 4 Ser linker followed by the synthetic VP64 activation domain was introduced downstream of the Flag-tagged dCas9 in plasmid pMLM3647 to yield plasmid pSL690. Using QuikChange sitedirected mutagenesis (Agilent), mutations resulting in D10A and H840A substitutions were also introduced into plasmid pJDS246, which contains sequence, codon-optimized for expression in human cells, that encodes a Flag-tagged Cas9, to yield plasmid pMLM3668. DNA sequence encoding the Gly 4 Ser linker and the VP64 activation domain were then cloned into pMLM3668 to yield an expression vector with codon-optimized sequence encoding dCas9-VP64, named pMLM3705. The full amino acid sequence of the dCas9-VP64 protein is shown in Supplementary  Figure 6 , and both dCas9-VP64 expression plasmids are available through Addgene (http://www.addgene.org/crispr-cas).
Cell culture and transfection. Human Flp-In T-Rex HEK293 cells were obtained from Life Technologies and cultured and transfected as previously described 12 . Cells were tested every 2 weeks for mycoplasma contamination. Briefly, all transfections were performed in triplicate using Lipofectamine LTX (Life Technologies). For transfections involving regulation of VEGFA, 160,000 cells were seeded into 24-well plates the day before transfection. 250 ng of plasmid encoding VEGFAtargeted sgRNA, 250 ng of plasmid encoding dCas9-VP64 or dCas9-VP64 (codon-optimized sequence) and 30 ng pmaxGFP plasmid (Lonza) were cotransfected using 0.5 µl PLUS reagent and 2.65 µl Lipofectamine LTX. For synergy experiments, the amount of each sgRNA was kept constant such that all transfections contained 62.5 ng of each sgRNA and empty U6 promoter plasmid was used to bring the total amount of plasmid to 250 ng. For transfections involving regulation of NTF3, 350,000 cells were seeded in 12-well plates the day before transfection. 100 ng, 250 ng or 500 ng of plasmid encoding NTF3-targeted sgRNA, 250 ng or 500 ng of plasmid encoding dCas9-VP64 (codonoptimized sequence) and 60 ng pmaxGFP plasmid (Lonza) were cotransfected using 1 µl PLUS reagent and 2.1 µl, 2.65 µl or 5.1 µl Lipofectamine LTX, respectively. For synergy experiments, the amount of each sgRNA was kept constant such that all transfections contained 83.3 ng of each sgRNA, and empty U6 promoter plasmid was used to bring the total amount of plasmid to 500 ng.
Enzyme-linked immunoblot assays of VEGFA protein.
Culture medium of Flp-In T-Rex HEK293 cells transfected with plasmids encoding VEGFA-targeted sgRNA and dCas9-VP64 was collected 40 h after transfection, and VEGFA protein expression was measured by ELISA as previously described 12 .
Quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Total RNA from Flp-In T-Rex HEK293 cells transfected with plasmids encoding NTF3-targeted sgRNAs and dCas9-VP64 (codon-optimized sequence) was isolated 2 d after transfection using the PureLink RNA Mini Kit (Ambion) and treated with TurboDNA-Free (Ambion) according to manufacturer's instructions. NTF3 mRNA levels were measured by qRT-PCR using a Taqman assay as previously described 12 Assessment of VEGFA-targeted sgRNAs for site-specific targeting of Cas9 nuclease in human cells. Transfections of HEK293 cells were performed as described for the dCas9-VP64 VEGFA experiments, except that cells were transfected with 125 ng of plasmid encoding VEGFA-targeted sgRNAs and 375 ng of plasmid encoding active Cas9 nuclease (pMLM3639). 40 h after transfection, genomic DNA was isolated using the QIAamp DNA Blood Mini kit (Qiagen) according to manufacturer's instructions. PCR amplification of the three different targeted regions in the VEGFA promoter was performed using Phusion Hot Start II high-fidelity DNA polymerase (NEB) with 3% DMSO and the following touchdown PCR cycle: 10 cycles of 98 °C, 10 s; 72-62 °C, -1 °C/cycle, 15 s; 72 °C, 30 s, followed by 25 cycles of 98 °C, 10 s; 62 °C, 15 s; 72 °C, 30 s. The region 500 bp upstream of the transcription start site was amplified using primers oFYF434 (5ʹ-TCCAGATGGCACATTGTCAG-3ʹ) and oFYF435 (5ʹ-AGGGAGCAGGAAAGTGAGGT-3ʹ). The region around the transcription start site was amplified using primers oFYF438 (5ʹ-GCACGTAACCTCACTTTCCT-3ʹ) and oFYF439 (5ʹ-CTTGCTACCTCTTTCCTCTTTCT-3ʹ). The region 500 bp downstream of the transcription start site was amplified using primers oFYF444 (5ʹ-AGAGAAGTCGAGGAAGAGAGAG-3ʹ) and oFYF445 (5ʹ-CAGCAGAAAGTTCATGGTTTCG-3ʹ). PCR products were purified using Ampure XP beads (Agencourt) and T7 endonuclease I assays were performed and analyzed on a QIAXCEL capillary electrophoresis system as previously described 16 .
Western blotting. Approximately 4 × 10 6 transfected cells were lysed in radioimmunoprecipitation assay protein extraction buffer (Cell Signaling), and supernatant was collected by centrifuging for 5 min at 4 °C. The concentration of the extracted protein was determined using a Thermo Scientific protein assay kit. Ten micrograms of extracted protein were run on a 4-12% Tris-glycine gel (Life Technologies) and electrotransferred to nitrocellulose membrane (Life Technologies). Membrane was blocked with 5% nonfat dry milk in Tris-buffered Saline-Tween buffer (25 mM Tris (pH 7.4), 137 mM NaCl, 2.7 mM KCl, 0.1% Tween 20) for 1 h at room temperature, and subsequently incubated with monoclonal Anti-Flag M2 antibody (Sigma, F3165) at a dilution of 1:7,500 and b-actin (C4) HRP monoclonal antibody npg (Santa Cruz Biotechnology, sc-47778) at a dilution of 1:40,000 in blocking buffer for 2 h at room temperature. Membrane was washed with TBS-T buffer and incubated with goat anti-mouse IgG (H+L) HRP-conjugate (Bio-Rad Laboratories, 172-1011) at a dilution of 1:10,000 in blocking buffer for 1 h at room temperature. The membrane was developed using ImmunoCruz chemiluminescence system (Santa Cruz Biotechnology) and exposed to BioMax XAR film (Kodak). npg
